コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rtality in acute or chronic lung disease and left heart failure.
2 ion in determining pulmonary hemodynamics in left heart failure.
3 he overlap of hemodynamic abnormalities with left heart failure.
4 s the spectrum of pulmonary hypertension and left heart failure.
5 n hemodynamic abnormalities in patients with left heart failure and global and regional lung perfusio
6 hors highlight differences between right and left heart failure and outline key areas of future inves
8 and comorbidities such as coronary disease, left heart failure, and chronic obstructive pulmonary di
10 ympathetic stimulation have been reported in left heart failure, but whether it would be beneficial f
11 een implicated in the development of chronic left heart failure, data describing such metabolic remod
13 ehind and many proven targeted therapies for left heart failure do not appear to provide similar bene
14 Contrasting with the major attention that left heart failure has received, right heart failure rem
15 ulmonary microvessel pressure experienced in left heart failure, head trauma, or high altitude can le
16 nts with kidney failure and may be driven by left heart failure, high cardiac output from arterioveno
17 onally relevant heart disease, predominantly left heart failure in combination with right heart failu
18 55), pulmonary arterial hypertension without left heart failure (n=18), and control subjects (n=30) u
19 how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utiliz
20 diac investigation revealed a combination of left heart failure, right heart failure and moderate-to-
21 y role of beta-blockers in the management of left heart failure, some authors have proposed to use th
23 As well, relative to our understanding of left heart failure, the basis for RHF remains poorly und